New antiviral therapies for hepatitis C

Expert Rev Anti Infect Ther. 2004 Apr;2(2):235-43. doi: 10.1586/14787210.2.2.235.

Abstract

Hepatitis C affects 170 million people worldwide and is the leading indication for liver transplantation. However, despite this high prevalence and burden of disease, current treatment regimens necessitate long durations of therapy, are often poorly tolerated and have suboptimal rates of sustained virologic response. Therefore, much attention has been directed at the development of new therapeutic agents against specific viral targets. This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Hepacivirus / physiology
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • IMP Dehydrogenase / antagonists & inhibitors
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • Liver Transplantation

Substances

  • Antiviral Agents
  • Immunologic Factors
  • IMP Dehydrogenase